Information Provided By:
Fly News Breaks for March 23, 2018
TNDM
Mar 23, 2018 | 08:26 EDT
As previously reported, Baird upgraded Tandem Diabetes to Outperform from Neutral and raised its price target to $7 from $3. Analyst Jeff Johnson has gone from thinking that Tandem may not survive to believing management may have the most compelling HCL system in diabetes by mid-2019. Johnson's newfound conviction in the product pipeline comes from management's prudent move of its t:slim X2 Insulin Pump system to a PMA versus 510(k) platform two years ago, that helped establish important relationships with FDA's PMA division. Further, the analyst believes Tandem's timeline for potential approval of its Control IQ system in 1H19 looks more reasonable than we previously realized, leading to a potential launch by mid-2019, and a head start over Medtronic's (MDT) 670G system and Insulet's (PODD) advanced HCL system.
News For TNDM From the Last 2 Days
TNDM
Mar 26, 2024 | 16:25 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
TNDM
Mar 26, 2024 | 12:08 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here